Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (6): 547-550.DOI: 10.3969/j.issn.1673-8640.2022.06.010
Previous Articles Next Articles
Received:2020-10-10
Revised:2021-12-21
Online:2022-06-30
Published:2022-07-28
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.06.010
| 组别 | 例数 | PLT计数/ （×109/L） | LDH/（U/L） | Hb/（g/L） | ALT/（U/L） | AST/（U/L） | TB/（μmol/L） | ||
|---|---|---|---|---|---|---|---|---|---|
| 非HELLP综合征组 | 354 | 132.77±18.67 | 261.14±28.52 | 112.33±10.29 | 36.79±9.86 | 45.21±13.72 | 12.57±2.14 | ||
| HELLP综合征组 | 63 | 67.21±13.57 | 778.44±25.08 | 108.62±12.44 | 78.65±15.33 | 94.76±21.14 | 28.78±3.53 | ||
| t值 | 28.464 | 134.952 | 2.550 | 28.205 | 24.057 | 49.407 | |||
| P值 | 0.000 | 0.000 | 0.011 | 0.000 | 0.000 | 0.000 | |||
| 组别 | UREA/（mmol/L） | Cr/（μmol/L） | PT/s | APTT/s | Fib/（g/L） | DD/（μg/mL） | TT/s | ||
| 非HELLP综合征组 | 4.67±1.27 | 54.24±6.39 | 13.67±0.36 | 35.89±1.96 | 3.90±0.81 | 0.71±0.22 | 14.58±1.97 | ||
| HELLP综合征组 | 10.26±1.96 | 82.31±7.17 | 13.71±0.27 | 36.22±1.67 | 3.24±0.79 | 0.89±0.23 | 14.88±1.89 | ||
| t值 | 29.306 | 31.521 | 0.841 | 1.257 | 5.981 | 5.942 | 1.120 | ||
| P值 | 0.000 | 0.000 | 0.401 | 0.209 | 0.000 | 0.000 | 0.263 | ||
| 组别 | 例数 | PLT计数/ （×109/L） | LDH/（U/L） | Hb/（g/L） | ALT/（U/L） | AST/（U/L） | TB/（μmol/L） | ||
|---|---|---|---|---|---|---|---|---|---|
| 非HELLP综合征组 | 354 | 132.77±18.67 | 261.14±28.52 | 112.33±10.29 | 36.79±9.86 | 45.21±13.72 | 12.57±2.14 | ||
| HELLP综合征组 | 63 | 67.21±13.57 | 778.44±25.08 | 108.62±12.44 | 78.65±15.33 | 94.76±21.14 | 28.78±3.53 | ||
| t值 | 28.464 | 134.952 | 2.550 | 28.205 | 24.057 | 49.407 | |||
| P值 | 0.000 | 0.000 | 0.011 | 0.000 | 0.000 | 0.000 | |||
| 组别 | UREA/（mmol/L） | Cr/（μmol/L） | PT/s | APTT/s | Fib/（g/L） | DD/（μg/mL） | TT/s | ||
| 非HELLP综合征组 | 4.67±1.27 | 54.24±6.39 | 13.67±0.36 | 35.89±1.96 | 3.90±0.81 | 0.71±0.22 | 14.58±1.97 | ||
| HELLP综合征组 | 10.26±1.96 | 82.31±7.17 | 13.71±0.27 | 36.22±1.67 | 3.24±0.79 | 0.89±0.23 | 14.88±1.89 | ||
| t值 | 29.306 | 31.521 | 0.841 | 1.257 | 5.981 | 5.942 | 1.120 | ||
| P值 | 0.000 | 0.000 | 0.401 | 0.209 | 0.000 | 0.000 | 0.263 | ||
| 组别 | 例数 | PT/s | APTT/s | Fib/（g/L） | DD/（μg/mL） | TT/s |
|---|---|---|---|---|---|---|
| 产后出血组 | 19 | 13.81±0.36 | 36.76±1.82 | 2.91±0.82 | 1.01±0.24 | 14.91±1.83 |
| 非产后出血组 | 44 | 13.67±0.34 | 35.98±1.79 | 3.38±0.85 | 0.83±0.21 | 14.86±1.97 |
| t值 | 1.474 | 1.579 | 2.035 | 2.990 | 0.196 | |
| P值 | 0.146 | 0.119 | 0.046 | 0.004 | 0.925 |
| 组别 | 例数 | PT/s | APTT/s | Fib/（g/L） | DD/（μg/mL） | TT/s |
|---|---|---|---|---|---|---|
| 产后出血组 | 19 | 13.81±0.36 | 36.76±1.82 | 2.91±0.82 | 1.01±0.24 | 14.91±1.83 |
| 非产后出血组 | 44 | 13.67±0.34 | 35.98±1.79 | 3.38±0.85 | 0.83±0.21 | 14.86±1.97 |
| t值 | 1.474 | 1.579 | 2.035 | 2.990 | 0.196 | |
| P值 | 0.146 | 0.119 | 0.046 | 0.004 | 0.925 |
| 组别 | 例数 | PT/s | APTT/s | Fib/（g/L） | DD/（μg/mL） | TT/s |
|---|---|---|---|---|---|---|
| 胎儿不良结局组 | 22 | 13.76±0.41 | 36.66±1.76 | 2.71±0.36 | 0.98±0.11 | 14.79±2.10 |
| 无胎儿不良结局组 | 41 | 13.68±0.39 | 36.00±1.98 | 2.94±0.34 | 0.90±0.12 | 14.93±1.99 |
| t值 | 0.762 | 1.309 | 2.508 | 2.594 | 0.261 | |
| P值 | 0.449 | 0.195 | 0.015 | 0.012 | 0.795 |
| 组别 | 例数 | PT/s | APTT/s | Fib/（g/L） | DD/（μg/mL） | TT/s |
|---|---|---|---|---|---|---|
| 胎儿不良结局组 | 22 | 13.76±0.41 | 36.66±1.76 | 2.71±0.36 | 0.98±0.11 | 14.79±2.10 |
| 无胎儿不良结局组 | 41 | 13.68±0.39 | 36.00±1.98 | 2.94±0.34 | 0.90±0.12 | 14.93±1.99 |
| t值 | 0.762 | 1.309 | 2.508 | 2.594 | 0.261 | |
| P值 | 0.449 | 0.195 | 0.015 | 0.012 | 0.795 |
| [1] | ENGJOM H M, MORKEN N H, HØYDAHL E, et al. Risk of eclampsia or HELLP-syndrome by institution availability and place of delivery-a population-based cohort study[J]. Pregnancy Hypertens, 2018,14:1-8. |
| [2] | SZEREMETA M, DROBULIAKOVA P, PRZEPIEŚĆJ, et al. An unusual medicolegal case of 32-year-old mother and her 29-week fetus with hemolysis,elevated liver enzymes,and low platelet count syndrome[J]. Am J Forensic Med Pathol, 2017, 38(3):269-271. |
| [3] | ABILDGAARD U, HEIMDAL K. Pathogenesis of the syndrome of hemolysis,elevated liver enzymes,and low platelet count(HELLP):a review[J]. Eur J Obstet Gynecol Reprod Biol, 2013, 166(2):117-123. |
| [4] | 中华医学会妇产科学分会妊娠期高血压疾病学组. 妊娠期高血压疾病诊治指南(2020)[J]. 中华妇产科杂志, 2020, 55(4):227-238. |
| [5] | 韩宁玉, 王欣. 产程时限与产后出血相关性的临床研究[J]. 中华妇产科杂志, 2020, 55(10):673-678. |
| [6] | 史峻梅, 杨孜, 李凤秋, 等. 血清白蛋白水平预警子痫前期发病的初步研究[J]. 中华妇产科杂志, 2020, 55(1):29-35. |
| [7] | 章彩萍, 徐秋莲, 朱敏. 重度子痫前期并发HELLP综合征影响因素分析[J]. 中华全科医学, 2018, 16(5):795-797. |
| [8] | 王晓临. 单胎妊娠重度先兆子痫并发HELLP综合征22例临床治疗分析[J]. 中国妇幼保健, 2015, 30(9):1349-1352. |
| [9] | GABOR M, DRAB M, HOLOMAN K. Postpartum corticosteroids in HELLP syndrome-standard to prompt recovery[J]. Bratisl Lek Listy, 2016, 117(7):418-424. |
| [10] | 郭楠楠, 黄颖. 成分输血配合限制性液体复苏在异位妊娠产后大出血合并失血性休克中的应用[J]. 中国妇幼保健, 2019, 34(1):197-200. |
| [11] | 康苏娅, 周丽屏, 汪云, 等. HELLP综合征期待治疗时间的探讨[J]. 国际妇产科学杂志, 2018, 45(1):46-50. |
| [12] | 吴军, 朱小晖, 蒋瑶, 等. 血清D-二聚体、FIB联合检测对妊娠期高血压综合征的早期预测价值[J]. 国际检验医学杂志, 2020, 41(10):1263-1266. |
| [13] | 胡鹏, 陈静飞. 妊娠期糖尿病及妊娠期高血压患者孕晚期凝血功能状态分析[J]. 检验医学, 2016, 31(9):774-777. |
| [14] | COLLINS P W, BELL S F, DE LLOYD L, et al. Management of postpartum haemorrhage:from research into practice,a narrative review of the literature and the Cardiff experience[J]. Int J Obstet Anesth, 2019,37:106-117. |
| [15] | 王留香, 王川红. 血浆FDP、D-D及血清NO、NOS与产后出血的关系研究[J]. 实验与检验医学, 2020, 38(3):462-465. |
| [16] | SAHIN A S, OZKAN S. Treatment of obstetric hemorrhage with fibrinogen concentrate[J]. Med Sci Monit, 2019,25:1814-1821. |
| [17] | 马思思, 兰晶, 张云聪, 等. 低纤维蛋白原水平是HELLP综合征产妇不良预后危险因素[J]. 中华检验医学杂志, 2019, 42(4):282-286. |
| [1] | DENG Chenxia, MEI Yanping, ZHANG Xia, HUANG Baoshan, TIAN Dan, CAO Mengting, HU Yongqi, LIN Yongping, TIAN Lijun. Depolymerization effect of optical platelet count on reversible platelet aggregation after blood collection [J]. Laboratory Medicine, 2023, 38(11): 1087-1090. |
| [2] | LU Tingyan, GU Danfeng, WANG Yahong, GE Yafang, YANG Haiou. Evaluation of vaginal secretion routine determination modes and review criteria analysis [J]. Laboratory Medicine, 2023, 38(11): 1091-1097. |
| [3] | . [J]. Laboratory Medicine, 2023, 38(11): 1098-1100. |
| [4] | . [J]. Laboratory Medicine, 2023, 38(10): 983-986. |
| [5] | . [J]. Laboratory Medicine, 2023, 38(9): 901-904. |
| [6] | . [J]. Laboratory Medicine, 2023, 38(9): 905-908. |
| [7] | CHENG Xu, YANG Cunqing, PANG Bo, GU Chun, HOU Xueyun, FEI Jiaxin, WU Min, LI Jun, LIU Guijian. Number and activity of peripheral blood eosinophils in obese people [J]. Laboratory Medicine, 2023, 38(9): 855-859. |
| [8] | LEI Jing, MAN Qiuhong, ZHAO Renjia, ZHANG Tiejun, JIANG Yanfeng, XU Kelin, SUO Chen, CHEN Xingdong. Elevated red blood cell distribution width increasing the risk of heart failure：a cohort study based on the UK Biobank [J]. Laboratory Medicine, 2023, 38(9): 860-864. |
| [9] | DUAN Lili, JIANG Chang, ZHOU Dongmei. Role of PLR in ankylosing spondylitis patients with positive antinuclear antibody [J]. Laboratory Medicine, 2023, 38(7): 669-674. |
| [10] | XIA Yanyan, XIA Yongquan, SONG Guanghao, XIA Mao. Role of coagulation-related monitoring indicators in the course of rivaroxaban anticoagulation for acute venous thromboembolism in elderly patients [J]. Laboratory Medicine, 2023, 38(5): 475-478. |
| [11] | CHEN Yi, WANG Jia, XU Zhiwei, ZHAI Yaping, XUAN Weixia. Effects of different anticoagulants on phagocytosis，activation and apoptosis of in vitro neutrophil function [J]. Laboratory Medicine, 2023, 38(5): 479-483. |
| [12] | YANG Liyuan, DAI Wanqin, WANG Xiaotong, LOU Xiaoli, WANG Yue, HOU Yanqiang. Effect of peripheral blood neutrophils on interferon-gamma release assay of Mycobacterium tuberculosis [J]. Laboratory Medicine, 2023, 38(5): 484-488. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(5): 502-504. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(1): 69-72. |
| [15] | XIE Yuan, YI Wanwan, SHI Qiuyuan, LÜ Zhongwei, LIU Jin. Clinical value of thromboelastography and conventional coagulation tests in evaluating coagulation status of colon cancer and colon polyps [J]. Laboratory Medicine, 2022, 37(11): 1007-1011. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
